Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05745389 · ClinicalTrials.gov registry record

CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry

A clinical trial of Alopecia Areata, sponsored by CorEvitas.

Recruiting
Registry status
5,000
Enrollment target
1
Study location

NCT05745389: Recruiting study of Alopecia Areata, sponsored by CorEvitas.

NCT05745389 is a study of Alopecia Areata that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 5,000 participants, above the 1,763-participant average among 26 other Alopecia Areata trials with a reported enrollment target (184% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05745389, a study of Alopecia Areata, is actively recruiting participants, sponsored by CorEvitas.

RECRUITING
Registry status
5,000 participants
Enrollment target
1
Study location

Study Summary

Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper limit for either target.

Primary Outcome

The major clinical outcomes include an assessment of the epidemiology of AA; to better understand the presentation, natural history, management and outcomes.

Conditions Studied

Study Locations (1)

Massachusetts

  • CorEvitas, LLC - Waltham

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2022-10-25
Est. Completion 2099-12-31
CorEvitas

13 total trials

What NCT05745389 shows while recruiting

NCT05745389 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,763-participant average among 26 other Alopecia Areata trials with a reported enrollment target (184% higher).

The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 0 interventions.

NCT05745389 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05745389 about?

NCT05745389 is a clinical study titled "CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry". Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper limit for either target.

What is the current status of trial NCT05745389?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2022-10-25. Estimated completion is 2099-12-31.

What conditions does trial NCT05745389 study?

This clinical trial studies the following conditions: Alopecia Areata.

Who is sponsoring clinical trial NCT05745389?

This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05745389 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alopecia Areata

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05745389's enrollment target sits among peer trials

5,000 3rd of 26 higher than 24 of 26 other Alopecia Areata trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alopecia Areata trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00060541 · 5,000 participants

    Evaluation and Treatment of Neurosurgical Disorders

  • NCT00575081 · 5,000 participants

    Physiological Brain Atlas Development

  • NCT00736749 · 5,000 participants

    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  • NCT00900198 · 5,000 participants

    Collection of Tissue Samples for Cancer Research

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05745389, the US trial registry maintained by the National Library of Medicine. NCT05745389 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.